RxDoctor Payments Data

Thriveni Vellore, MD

Family Medicine · Houston, TXNPI 1225003270

Payments from drug & device makers

$4,194in general payments, 2019–2025

Across 125 payments — averaging $33.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$586
  • Novo Nordisk$585
  • Astellas Pharma US Inc$415
  • Lilly USA, LLC$415
  • AbbVie$251
  • plus $811 from 9 others

What the payments were for

  • Food & beverage$4,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca23$1,131
GSK31$586
Novo Nordisk18$585
Astellas Pharma US Inc12$415
Lilly USA, LLC13$415
AbbVie4$251
Pfizer5$175
Medtronic2$158
Amgen(2 entities)3$157
Dexcom, Inc.4$142
Merck4$72
Abbott3$54
Sanofi Pasteur Inc.1$22
Gilead1$15
Eisai Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,194 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$45,749
Medicare patients
197
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$12,909
Fluticasone Propionate57$1,467
Montelukast Sodium90$837
Albuterol Sulfate HfaAlbuterol Sulfate30$814
Atorvastatin Calcium62$463
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav54$349
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$339
Levothyroxine Sodium35$316
Mirtazapine16$314
Omeprazole20$249
Doxycycline Hyclate29$220
Gabapentin38$195
Metformin Hcl ErMetformin Hcl19$175
Tamsulosin Hcl14$171
Losartan Potassium27$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$585$12,90915 claims
PfizerPaxlovid$175$014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →